$SION
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Healthcare
Sector
Biotechnology
Industry
Michael Cloonan
CEO
41
Employees
$45.95
Current Price
$1.84B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $17,068,029.16 | 369,278 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $26,728,129.00 | 585,904 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 8 | $26,990,618.92 | 591,800 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 16 | $77,562,901.84 | 1,717,760 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 17 | $77,909,920.72 | 1,728,010 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 11, 2026 | Thompson Peter A. Director | Sale | 184,639 | $46.22 | $8,534,014.58 | View Details |
| May 8, 2026 | Thompson Peter A. Director | Sale | 59,767 | $44.58 | $2,664,412.86 | View Details |
| May 7, 2026 | Thompson Peter A. Director | Sale | 48,546 | $44.61 | $2,165,637.06 | View Details |
| May 8, 2026 | ORBIMED ADVISORS LLC Director | Sale | 59,767 | $44.58 | $2,664,412.86 | View Details |
| May 7, 2026 | ORBIMED ADVISORS LLC Director | Sale | 48,546 | $44.61 | $2,165,637.06 | View Details |
| May 11, 2026 | ORBIMED ADVISORS LLC Director | Sale | 184,639 | $46.22 | $8,534,014.58 | View Details |
| Apr 18, 2026 | Thompson Peter A. Director | Sale | 2,948 | $44.52 | $131,244.96 | View Details |
| Apr 17, 2026 | Thompson Peter A. Director | Sale | 52,397 | $44.68 | $2,341,097.96 | View Details |
| Apr 17, 2026 | ORBIMED ADVISORS LLC Director | Sale | 52,397 | $44.68 | $2,341,097.96 | View Details |
| Apr 18, 2026 | ORBIMED ADVISORS LLC Director | Sale | 2,948 | $44.52 | $131,244.96 | View Details |
| Apr 14, 2026 | Thompson Peter A. Director | Sale | 47,814 | $44.51 | $2,128,201.14 | View Details |
| Apr 15, 2026 | Thompson Peter A. Director | Sale | 235,863 | $44.64 | $10,528,924.32 | View Details |
| Apr 16, 2026 | Thompson Peter A. Director | Sale | 226,906 | $45.34 | $10,287,918.04 | View Details |
| Apr 16, 2026 | ORBIMED ADVISORS LLC Director | Sale | 226,906 | $45.34 | $10,287,918.04 | View Details |
| Apr 14, 2026 | ORBIMED ADVISORS LLC Director | Sale | 47,814 | $44.51 | $2,128,201.14 | View Details |
| Apr 15, 2026 | ORBIMED ADVISORS LLC Director | Sale | 235,863 | $44.64 | $10,528,924.32 | View Details |
| Mar 5, 2026 | Fitzpatrick Jennifer Chief Legal Officer | Sale | 10,250 | $33.86 | $347,018.88 | View Details |
135 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.61
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$TRAW โ Traws Pharma, Inc.via ORBIMED ADVISORS LLC$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$PRLD โ Prelude Therapeutics Incvia ORBIMED ADVISORS LLC$STTK โ Shattuck Labs, Inc.via ORBIMED ADVISORS LLC$EWTX โ Edgewise Therapeutics, Inc.via Thompson Peter A.$ACET โ Adicet Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$MBX โ MBX Biosciences, Inc.via ORBIMED ADVISORS LLC$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.